

KANEH BOSM BIOTECHNOLOGY INC.

810 – 675 West Hastings Street

Vancouver, BC V6B 1N2

Tel: 604.782.4191

NOT FOR DISSEMINATION IN THE UNITED STATES

NEWS RELEASE

September 11, 2017 – Vancouver, BC. - Kaneh Bosm BioTechnology Inc. (the “Company”) (CSE: KBB) Closes First Tranche \$380,375 of Previously Announced Private Placement

Kaneh Bosm BioTechnology Inc. (KBB:CSE) (“Kaneh Bosm” or the “Company”) is pleased to announce the Company has closed its first tranche of its previously announced non-brokered private placement. The first tranche was for 7,245,238 out of the total 14,285,714 special warrants for gross proceeds of \$380,375 out of the \$750,000. Each special warrant was priced at \$0.0525 per special warrant. Each special warrant will entitle the holder to receive, without payment of any additional consideration or need for further action, one unit of the company, each unit comprising one common share and one share purchase warrant, each warrant entitling the holder to acquire one additional share at seven cents for a period of 24 months. The special warrants will convert to units on the earlier of four months and a day after closing of the placement, and the receipt of a final prospectus qualifying the shares and underlying warrants.

The proceeds of the private placement will be used for general working capital and potential acquisitions.

The Company expects to close the 2nd tranche soon following this news release.

On behalf of the Board of Directors of Kaneh Bosm Biotechnology Inc.

“Rudy de Jonge”

Rudy de Jonge

CEO, Director

rudydejonge@hotmail.com

(604) 782-4191

THE CSE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com